Interpace Diagnostics

The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.

The firm will begin selling its ThyGeNext thyroid cancer diagnostic tool to physicians in New York and Pennsylvania in combination with ThyraMir.

Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.

Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.

The tests have received coverage decisions from a number of Blue Cross Blue Shield plans this year including ones in California and New Jersey.

The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.

The payor published positive medical policy coverage for the ThyGenX and ThyraMir assays for thyroid nodules deemed indeterminate by standard cytopathological analysis.

Under the new agreement, physicians can order both thyroid biopsy analysis and molecular testing from Interpace, and LabCorp's Dianon Pathology, will be available to do biopsy analysis.

Pages

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.